It’s spectacular how fast this industry is changing. One example is Diagenic which offers peripheral blood-based diagnostic tests for breast cancer or Alzheimer’s disease (though it’s gene expression based). And now Medgadget reported about a new solution designed by Progenika BioPharma for Familial Lipoprotein Lipase Deficiency.
In collaboration with AMT, Progenika Biopharma has developed the LPLchip which detects mutations in the LPL gene, and has now received CE approval.
The chip can detect 120 different mutations in a sample of blood or saliva, enabling identification of patients who may benefit from gene therapy. So far, the picture for Glybera is looking good, with three studies showing a decrease in the incidence of pancreatitis, one of the most important complications of LPLD, in patients undergoing treatment. Expect to hear more about this in the future.
At this year’s Researchers’ Night, I talked about genomic medicine and I described the future of healthcare which would be personalized-centric and I said this era would come in around 10 years. It seems I was wrong and this transition will be much faster.